Trends in Sentinel Lymph Node Mapping and Adjuvant Therapy in Endometrial Carcinoma

Cancer Invest. 2018 Mar 16;36(3):190-198. doi: 10.1080/07357907.2018.1449212. Epub 2018 Mar 22.

Abstract

We analyzed 54,039 women with uterine cancer in the National Cancer Database from 2013 to 2014 including 38,453 (71.2%) who underwent lymphadenectomy, 1929 (3.6%) who underwent sentinel lymph node (SLN) mapping, and 13,657 (25.3%) who did not undergo nodal assessment. SLN mapping increased from 2.8% in 2013 to 4.3% in 2014 (P < 0.001). Patients treated in 2014 and those at community centers were more likely to undergo SLN biopsy, while women with advanced-stage disease, sarcomas, and grade 3 tumors were less likely to undergo SLN mapping (P < 0.05). There was no association between use of SLN biopsy and use of radiation (aRR = 0.92; 95% CI, 0.82-1.05).

Keywords: Endometrial cancer; Hysterectomy; Lymphadenectomy; Sentinel lymph node; Uterine cancer.

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • Endometrial Neoplasms / pathology
  • Endometrial Neoplasms / therapy*
  • Female
  • Humans
  • Lymph Node Excision / trends*
  • Middle Aged
  • Neoplasm Grading
  • Neoplasm Staging
  • Retrospective Studies
  • Sentinel Lymph Node / pathology*
  • Sentinel Lymph Node Biopsy / trends*